Replimune Group, Inc.'s (NASDAQ:REPL) Chief Medical Officer, Xynos Konstantinos, recently sold shares of the company stock valued at approximately $41,194. The transaction involved the sale of 6,367 shares at an average price of $6.47 per share.
The sale, which took place on May 16, 2024, was part of a pre-arranged plan to cover tax withholding obligations connected to the partial vesting of Konstantinos's Restricted Stock Units (RSUs). This disposal of shares was conducted in accordance with the "sell to cover" provision outlined in the award agreements under which the RSUs were granted. It is important to note that this sale was not a discretionary transaction by the reporting person.
The shares were sold in multiple transactions with prices ranging between $6.46 and $6.56. Following this sale, Konstantinos still holds a substantial number of shares in Replimune Group, totaling 133,012 shares of common stock.
Investors and interested parties can request detailed information about the exact number of shares sold at each specific price within the range from the company, as per the footnotes in the SEC filing.
Replimune Group, Inc., based in Woburn, Massachusetts, operates within the biotechnology sector, focusing on the development of biological products. The company's stock trades on the NASDAQ under the ticker symbol REPL.
InvestingPro Insights
In the wake of Replimune Group, Inc.'s (NASDAQ:REPL) recent insider stock transaction, investors may find it informative to consider the company's financial health and market performance through various metrics. According to InvestingPro data, Replimune Group holds a market capitalization of $364.81 million USD. The company's Price to Earnings (P/E) Ratio stands at -1.81, reflecting its current earnings deficit. Furthermore, the stock has experienced a significant decline over the past year, with a 1 Year Price Total Return of -69.66%, trading near its 52-week low at 23.94% of the high.
From the suite of InvestingPro Tips, it is noted that Replimune Group does not pay a dividend to shareholders (Tip 9), which might be a consideration for income-focused investors. Additionally, analysts do not anticipate the company will be profitable this year (Tip 4), which could influence investor sentiment regarding future growth potential. For those interested in exploring further, there are additional InvestingPro Tips available, which can provide deeper insights into Replimune Group's financials and market outlook.
Investors looking to gain a comprehensive understanding of Replimune Group's prospects may benefit from the detailed analysis provided by InvestingPro. To access these insights, visit https://www.investing.com/pro/REPL. For those considering a subscription, use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.